Infectious agents and their hosts interact in a complex manner, involving not only superficially apparent mechanisms, but also the signaling machinery that governs host cells responses. Thus, signaling events, surface molecule expression, and transcriptional control may be affected in various cell types, with profound consequences for the function of individual cells and organ systems. Studies of the biochemistry of cell signaling and cell invasion by infectious agents have begun to detail the interplay between elements of infectious organisms and the host at the molecular level. Consequently, the resulting interferences with lymphocyte signaling may disturb the function of the immune system. In B cells, alterations of immune receptor signaling has implications for human diseases. By affecting the mechanisms of the host's immune defense, this may not only lead to inadequate elimination of an infectious agent, but also to autoimmunity or neoplasia.
Introduction
As their hosts evolved mechanisms to thwart infection and disease, infectious agents have adopted manifold strategies to survive in their hosts and, eventually, to cause disease. Antigenic shift of lentivirus coat proteins allows evasion from neutralizing antibodies. 1 The absence of viral protein presentation on the surface of neurons latently infected with herpes simplex virus (HSV) 2 and suppression of MHC class I expression by adenoviruses 3, 4 are examples of how pathogens may avoid recognition by T cells. Decreased expression of cell adhesion molecules, as occurs with Epstein-Barr virus (EBV) in Burkitt's lymphoma, 5 may also compromise T-cell interactions with infected target cells. More recently, unsuspected mechanisms underlying subversive effects of infectious agents have been identified. As they bind to cell-surface molecules, even before gaining entry into cells, viruses may disturb and subvert physiologic signaling. After cellular entry, they continue to exploit molecules and signaling pathways of the host to ensure their survival and to promote their replication. Transcription of viral components and release of infectious particles further compromise cellular signaling. Here, we discuss the impact of interactions between B lymphocytes and infectious agents on signal transduction and on pathogen propagation.
Interaction with cell-surface receptors critical for B-lymphocyte signaling
The best characterized interaction of an infectious agent with B lymphocytes is that of EBV, a ubiquitous human B-lymphotropic herpes virus with a worldwide prevalence of approximately 95%. Viral latent persistence without apparent disease is a hallmark of EBV infection, and occurs in at least three forms characterized by the differential expression of six EBV nuclear antigens termed EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNALP, and three integral latent membrane proteins termed LMP1, LMP2A, and LMP2B. The expression of five of them (EBNA1, EBNA2, EBNA3a, EBNA3c, and LMP1) is essential for immortalization of B cells (reviewed in Refs.6,7). At least three of these EBV gene products have been shown to subvert B-lymphocyte signaling. EBV causes a broad variety of disorders, from infectious mononucleosis, a self-limiting lymphoproliferative disease, to Burkitt's lymphoma, Hodgkin's disease and, in immunocompromised individuals, immunoblastic lymphoma, for example, AIDS-associated lymphoma. It is also associated with certain rare T-cell lymphomas, poorly or nondifferentiated nasopharyngeal carcinoma, and epithelial oral hairy leukoplakia. 7 In vitro, EBV has the propensity to transform and immortalize B cells, allowing derivation of cell lines. It uses its major outer membrane glycoprotein gp350/220 to bind to CR2 (CD21), the cell surface receptor for the third complement component (C3d) and IFN-a. 8 CD21 plays a major role in a signaling complex comprising sIgM, 9 CD19, 10 TAPA-1 (target of antiproliferative antibody-1), [10] [11] [12] and CD23. 13 Several other viral interactions with surface receptors critical for immune cell signaling have been identified. First, the receptor for poliovirus is an integral membrane protein with the conserved amino acid sequences and domain structures characteristic of the immunoglobulin (Ig) superfamily.
14 Second, although still controversial, it is thought that the IgA receptor may serve as a receptor for the hepatitis B virus in humans. 15 Third, the human signaling lymphocyte activation molecule (SLAM; also known as CDw150), which is expressed on B cells, T cells, and dendritic cells, has been identified as a receptor for surface binding and cell entry of mobilliform viruses. 16 In B cells, ligation of SLAM enhances activation, proliferation, and Ig synthesis. 17 Disturbance of these functions could account for the immunosuppression induced by the measles virus. Of additional interest is that mutations of the SLAM-associated protein (SAP, SHD1A, DSHP) are responsible for human X-linked lymphoproliferative disease, in which absence of the inhibitory properties of SAP is associated with fulminant EBV infection. 18 Fourth, entry of many strains of HSV is mediated by glycoprotein D, a structural component of the HSV envelope that interacts with a member of the tumor necrosis factor receptor superfamily. 19, 20 Fifth, HIV-1 uses CD4 and chemokine receptors to infect target cells. 21, 22 Finally, the myxoma virus M-T7 protein functions as a soluble homologue that can bind to and inhibit the biological activities of interferon-gamma with high affinity in a species-specific manner. 23 
Pleiotropic consequences of cell receptor ligation
Studies of EBV-immortalized B lymphocytes and of transgenic mouse models have led to the identification of a score of intricate subversive effects of this virus on B-cell signaling. Upon gp350/220 ligation, CD21 caps together with sIgM, and the capped molecules and EBV particles are endocytosed into coated vesicles followed by their release into the cytoplasm. 24 HLA-DR MHC class II molecules and a complex of three glycoproteins, gH, gL and gp42, of which the latter binds to HLA-DR, also participate in this process. 25 One effect of EBV binding to CD21 is activation of phosphatidyl-inositol 3-kinase (PI3-K) 26 and rapid activation of NF-kB via PI3-K, PKC, and protein tyrosine kinases (PTKs). 27 The activation ofNF-kB increases the expression of IL-1, IL-6, TNFa, and IL-2 27, 28 and mediates transcription of the viral latent gene promoter Wp. 29 Thus, binding of EBV to B lymphocytes results in the removal of receptors from the cell surface, provides activation signals related to cytokine production, and leads to expression of the initial viral gene promoter Wp. Other potential effects, such as modification of CD21 binding of cytoplasmic p53 and p68, and the nuclear p120 ribonucleoprotein, 30 have yet to be addressed in detail.
Interference with normal B-cell receptor signaling
A remarkable property of some viruses is to directly take advantage of signals normally arising from the B-cell receptor (BCR). In the case of EBV, LMP2A aggregation in the plasma membrane of nonproliferating peripheral B cells disrupts BCR signaling (Figure 1a) . 31, 32 It inhibits Ca 2+ influx and prevents physiologic tyrosine phosphorylation by binding the PTKs Syk and Lyn. 33 While phosphorylation of LMP2A tyrosine 112 by Lyn enables its association with this PTK, 34 phosphorylation at tyrosines 74 and 85 within the LMP2A immunoreceptor tyrosine activation motif (ITAM) allows binding of Syk through the Syk tandem SH2 domains, and Syk tyrosine phosphorylation and activation. 35 Subsequently, LMP2A recruitment of Syk and Lyn to the antiapoptotic serinethreonine kinase Akt constitutively induces the PI3-K phosphorylation critical for Akt activation. 33, [36] [37] [38] By phosphorylating and inactivating glycogen synthase kinase 3, activated Akt promotes cell survival by nuclear accumulation of transcription factors that alter transcription. 37 In addition, the proline-rich cytoplasmic regions of LMP2A bind multiple WW domains of the E3 protein-ubiquitin ligases of the Nedd4 family to form complexes that enhance Lyn and Syk ubiquitination in vivo and reduce levels of Lyn. 39 The specificity of these effects of LMP2A, which are mediated by a clustering signal at the C-terminal domain of this molecule, 40 has been demonstrated by the expression of a mutant LMP2A, which, in contrast to wild-type LMP2A, allows the recruitment of Lyn, Syk, PI3-K, PLCg-2, Vav, Shc, and MAPK in response to BCR activation. 33 Thus, LMP2A diverts Syk and Lyn from their physiologic interactions, enhances the degradation of Lyn, and directs their activity toward a pathway that promotes cell survival.
There is mounting evidence that other viruses also subvert signaling through the BCR. The retroviral bovine leukemia virus causes a persistent increase in peripheral blood B-lymphocyte counts and, in some animals, progression to B-cell leukemia and/or lymphoma. Recently, it was found that the B-cell protein tyrosine phosphatase (PTPase) SHP-1 associates with the viral transmembrane protein, gp30, indicating that gp30 acts as a decoy to sequester SHP-1. 41 The removal of this downregulatory PTPase could promote signaling through the BCR, representing yet another mechanism for viral activation of B lymphocytes.
A similar phenomenon occurs in Kaposi sarcoma (KS)-associated herpesvirus (KSHV; also known as human herpesvirus 8, HHV8) infection. In addition to causing KS, the most frequent neoplasia in HIV-infected patients, KSHV is closely linked to the B-cell lymphoproliferative disorders such as primary effusion lymphoma and plasmablastic, multicentric Castleman's disease. In B cells, its natural reservoir, KSHV expresses K1, a transmembrane protein with a functional ITAM. Without exogenous stimulation, K1 is able to initiate constitutive Ca 2+ signaling and activation of Syk and PLCg-2. 42 Other data indicate that K1 is responsible for low-grade lytic replication in vivo. 43 A total of 10-15% of KSHV-positive plasmablasts express high levels of virally encoded IL-6 (vIL-6), 44 which may further enhance its pathogenic properties. Thus, K1-mediated signaling may participate in viral transcriptional activation and reactivation from latency, and drive the differentiation of KSHV-infected naive B cells into plasmablasts and toward lymphoproliferative transformation. A close relative of KSHV, the rhesus monkey rhadinovirus (RRV), a gamma-2 herpesvirus, produces a transmembrane signaling protein, R1, that also promotes cell growth and transformation. Its cytoplasmic domain contains several tyrosine residues whose phosphorylation by Syk elicits B-lymphocyte activation similar to K1. 45 Therefore, in each of these cases, a single viral protein is capable of interfering with signals normally arising from the BCR, and of targeting proximal or distal pathways to promote activation, cell survival, latency and transformation. As will be discussed below, these observations are probably relevant to viral infection in vivo. Reminiscent of these subversive effects of viruses on BCR signaling are the properties of some microbial products. Bacteria produce many toxins that bind specifically to HLA class II molecules and certain Vb T-cell receptors. As a result of their capacity to stimulate a greater proportion of T lymphocytes than peptide antigens without a requirement for antigen processing, they have been termed 'T-cell superantigens'. 46 It appears that some microbial products also target human B lymphocytes. They affect proliferation and Ig production in response to antihuman IgM, and induce protein tyrosine phosphorylation and activation of PLC and PKC. 47, 48 Some of them, such as protein G of group C and G streptococci, and protein H of Streptococcus pyogenes, interact with specific portions of the Ig constant regions. 49 Similarly, expression of Fc receptors by HSV-1 and 2, varicella-zoster virus and human CMV allows these viruses to directly interact with host Igs, to interfere with humoral immunity and to modify the host B-cell response. [50] [51] [52] Even more intriguing is the potential of other infectious agents to produce molecules, referred to as 'B-cell superantigens', 49, 53 capable of interacting specifically with the Ig H-or L-chain variable regions, independent of the epitope binding site. This group of microbial products, which includes protein A of Staphylococcus aureus, gp120 of HIV-1, protein L of Peptostreptococcus magnus (reviewed in Ref. 54 ), can trigger a cascade of signaling events, with PTK and PLC stimulation and, ultimately, activation of MAP kinase. 55 In experimental animals, one B-cell superantigen was shown to have profound effects on B lymphocytes in both neonatal and adult mice. 56 Additional studies are required to elucidate the signaling pathways that lead to such extensive B-cell alterations.
Substituting for the absence of a functional BCR
To survive, developing B cells must avoid elimination at several checkpoints, including the requirement for successful IgH-chain rearrangements and BCR assembly. As discussed above, in the absence of a functionally competent BCR, LMP2A provides in vitro constitutive survival signals for mature B cells. Not unexpectedly, in vivo transgenic expression of LMP2A enables B-cell progenitors to survive censoring for successful rearrangement and expression of functionally viable IgHchains. 57 Even the loss of sIg expression caused by LMP2A, an alteration expected to result in rapid apoptosis, 58 fails to prevent cell survival and proliferation. 59 Consequently, nontransformed cells lacking pre-BCR and BCR expression predominate in the bone marrow and periphery of LMP2A transgenic mice. 57 The specificity of LMP2A activity was confirmed by the absence of developmental abnormalities or survival phenotypes in EmLMP2A BCRÀ transgenic mice expressing a mutant LMP2A ITAM. 60 Thus, LMP2A allows B-cell survival and development in the absence of physiologic signals under the condition that its ITAM is functional. Because LMP2A can substitute for antigen drive in mature B lymphocytes, it is probably important for the virus to gain access to the memory B-cell pool.
Mimicking B-lymphocyte activation signaling
In addition to blocking physiologic BCR signaling and substituting for a functional BCR, EBV can mimic physiologic signaling via CD40, a member of the tumor necrosis factor family of receptors (TNFR) that initiates signaling by transmitting growth signals to the nucleus through cytoplasmic TNFR-associated factors (TRAFs). This property is mediated by LMP1, an integral membrane protein expressed in latently infected B cells, and oncogenic even in nonlymphoid cells. 61 Structures shared with TNFRs allow LMP1 to emulate constitutive activation of CD40 ( Figure 1B) by activating the transcription factor NF-kB and binding to certain TRAFs. 62 This is accompanied by binding of an NF-kBlike factor to kB sequences within the A20 promoter to induce expression of A20, an inducible zinc-finger protein that enhances resistance to TNF-a cytotoxicity. 63 The cytoplasmic C-terminus of LMP1 interacts with TRAF2 and TRAF1, and binds to the p80 TNFR, CD40, and the lymphotoxin-b receptor, while a different EBVinduced protein, EB16, associates with the p80 TNFR 64 to activate NF-kB by aggregation with TRAF-1 and À2. 65 This is compatible with the finding that LMP1 activation of NF-kB is not dependent on the sequences mediating signal propagation of the p55 TNFR or on interaction with receptor-interacting protein (RIP). 66 Thus, by acting like a constitutively activated TNFR, LMP1 emulates activation signals triggered by CD40 signaling. 67 Furthermore, proliferation of EBV-transformed B cells requires continuous expression of LMP1, in a manner resembling CD40-CD154-induced B-cell activation via NF-kB and c-Jun terminal kinase (JNK) signaling. 67 Likewise, in addition to the TRAF interaction domain of LMP1, a distinct C -terminal domain activates the JNK pathway and the AP-1 transcription factor. 68 Other B-cell effector functions induced by oligomerization of the 200 carboxyl terminal residues of LMP1, such as rescue from BCR-mediated growth arrest, and secretion of Ig and IL-6, are practically identical to those arising in response to CD40 signaling. 69 There is also evidence that a C-terminal region of LMP1 initiates JAK phosphorylation, implying modification of STAT signaling by EBV. 70 Conversely, LMP1 originating from EBVinfected cells is capable of suppressing activation of T cells and inducing T-cell anergy, a paradox that awaits full explanation. 71 
Subversion of early-and late-signaling events
Another strategy of modifying signaling by substituting for physiologic factors is used by the African swine fever virus (ASFV) that causes a highly contagious, hemorrhagic disease in pigs with extensive B-cell loss and nonspecific hypergammaglobulinemia. This may be explained by the downregulation of surface CD21, and by the severe apoptosis of B cells, unless they are rescued by CD40L expressed on activated T cells. 72 This activity may be related to the presence of A238L, a viral protein with sequence similarities to IkB. On the one hand, it acts like cyclosporin by binding to calcineurin, which stabilizes A238L, 73 and by inhibiting dephosphorylation and nuclear translocation of NFAT. 74 On the other hand, A238L dissociates NF-kB from IkB by activating the NF-kB pathway, leading to a rapid physiologic degradation of IkB. A238L itself can then bind to the free p65 NF-kB, effectively blocking NF-kB signaling owing to the insensitivity of the resulting dimer to activation. 75 That A238L protein is able to modulate NF-kB activity in vitro suggests an important role in viral pathogenesis. However, deletion of this protein has no effect on the ability of ASFV to replicate in vitro or in vivo. 20, 76 As in other circumstances, many of the ''immune evasion'' genes have only been characterized in vitro, and very few examples exist of subversive genes that have definitively been shown to play a role in viral pathogenesis.
Similar subversive properties have also been identified in retroviral infection targeting B lymphocytes. First, B cells from mice with MAIDS, a retrovirus-induced acquired immunodeficiency syndrome, show an early IgM-signaling alteration and a generalized defect in B-cell proliferative responses. 77 Apart from alterations in multiple tyrosine phosphorylation events, there is a reduction of Ca 2+ influx, an impaired tyrosine phosphorylation response to IgM crosslinking or to PMA plus Ca 2+ ionophore. Second, Abl/myc-and raf/myc-containing retroviruses subvert JAK-STAT signaling, resulting in in vitro loss of IL-7 dependence, and pre-B-cell transformation, and in B-cell tumors in BALB/c mice. 78 Third, soluble Tat, a biologically active extracellular protein released by infected cells in HIV-positive patients, affects B-cell differentiation and may favor the development of AIDS-associated B-cell lymphomas. 79 This may be caused by modulation of cyclin-dependent kinase activity or by prolonged survival of germinal center B cells, probably by interfering with the DNA-binding activity of NF-kB.
Transcriptional modulation of B-lymphocyte gene expression
EBV drives B cells to proliferate through the expression of nine latent proteins under the control of the transcription factor EBNA2. 80 By acting as a transcriptional modulator of cellular and viral gene expression, EBNA2 plays a pivotal role in B-cell immortalization. It activates the transcription of CD21 and CD23 81 and the PTK c-Fgr, 82 and downregulates expression of the IgHchain locus. 83 Importantly, EBNA2 interacts with the transcription factor RBP-J, a protein highly conserved in evolution F from nematodes to humans F that acts downstream of the receptor Notch. 84 In Drosophila, Notch is expressed throughout development and influences cell fate decisions. Notch homologs isolated from vertebrates, including mice and humans, play a role in cell-type determination at multiple steps of differentiation, particularly in the hematopoietic system. 85, 86 For example, Notch signaling affects the maturation of thymocytes, 87 the choice between CD4 and CD8 T cells, 88 and between 89 Recently, it was shown that the intracellular domain of Notch1 is active in B cells and that it participates in gene regulation in a manner similar to that of EBNA2. 90 Therefore, EBNA2, which is consistently expressed in the naive IgD + B-cell subset of healthy tonsils, 91 may be regarded as a functional homolog of activated Notch. The molecular mechanisms underlying transcriptional regulation and its functional consequences in B lymphocytes remain the focus of investigation. Recently, the EBV BART (BamHI-A rightward transcript) RPMS1 has been found to encode for a protein that colocalizes with Notch1C and EBNA2 and negatively regulates EBNA2 and Notch1 signaling. 92 
Conclusions
It is remarkable that persisting infectious agents have a predilection to affect the nervous and the immune systems. For example, lymphocytes can be infected with a number of viruses, including cytomegalovirus, EBV, HHV-6, HHV-8, adenoviruses, HIV and human T-cell leukemia viruses 1 and 2. While the relative isolation of the nervous system from the immune system may favor persistence of infectious agents in that location, subverting the immune system itself offers manifold opportunities for pathogens to ensure their survival and persistence. Thus, it is not surprising that the observations detailed above show that infectious agents target a variety of molecules and B-lymphocyte signal transduction pathways, in order to avoid detection and destruction, and to shift the outcome of infection to their advantage (Table 1) .
From the point of view of the immune system, the interaction between the mammalian host and infectious agents has, throughout evolution, shaped an array of defenses against the continuous assault by pathogens. Reciprocally, from their point of view, infectious agents have developed efficient strategies to survive and persist in the infected host. 93 In the case of EBV, subversion of B-cell signaling releases B lymphocytes from the constraints of T-cell help, accessory molecule costimulation, cytokine dependence for growth and proliferation, and inhibitory cytokines, while disallowing anergy and programmed cell death. HHV-8 is another example of the ability of a virus to promote B-lymphocyte activation pathways. The consequences are not limited to B-cell proliferation and antibody production, since altered expression of surface molecules and cytokine profiles affect interactions with other cell types. It is intriguing that infectious agents are able to mimic a general mechanism for promoting immune cell signaling. Recently, crosslinking of surface immune receptors has been shown to result in the enrichment of these receptors in glycosphingolipid-and cholesterol-rich plasma membrane microdomains, termed lipid rafts, along with other downstream signaling molecules. 94 Under physiological conditions, the coordinated aggregation of functional elements in lipid rafts is required for both signal transduction and membrane trafficking. 95 Remarkably, some pathogens can target signaling molecules through rafts and use them to enter into host cells. For example, LMP2A locates to rafts in B lymphocytes in a manner dependent on Lyn phosphorylation and, in addition to its other effects, disrupts BCR signaling as well as antigen internalization.
96 LMP1 also associates with rafts, from which it links to the cytoskeleton via a TRAF-interacting domain. 97 Even for HIV-1, the infectious potential depends on intact lipid rafts. 98 Finally, the subversion of B-lymphocyte signal transduction by infectious agents deserves consideration with respect to the critical role of signaling in autoimmunity. 99 Mounting evidence indicates that a tight control of signaling pathways and highly coordinated interactions of several transmembrane and cytosolic proteins are required for appropriate signaling through the BCR to avoid overt autoimmunity. In as much as infectious agents alter immune receptor signaling by interacting with signaling molecules that critically guide optimal immune self-nonself discrimination, it is conceivable that EBV and other agents interfere with normal signaling and disrupt the balance of normal B-lymphocyte signaling. The cumulative effect of faulty signaling because of latently persisting, highly prevalent infectious agents may complement, or even outweigh, the genetic background in causing autoimmune disease. Such a scenario is compatible with the implication of infectious agents in human autoimmune diseases 100, 101 (reviewed in Refs. 102, 103) . A more complete understanding of the subverted pathways may provide the basis for targeted therapies of diseases related to infection, perhaps including autoimmune diseases.
